News

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Patholytix Foresight, a non-clinical artificial intelligence (AI) decision support tool developed in

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd

Novocure (NASDAQ: NVCR) today announced 20 presentations on Tumor Treating Fields (TTFields) therapy will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2024, to

Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus, a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good

Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus, a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its first quarter 2024 results on Wednesday, May 1, 2024, after the close of the market. Acadia will conduct a

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced a collaboration with Uber Health (NYSE:UBER). The two companies are coming together to improve access to life-saving behavioral health

Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the first quarter ended March 31, 2024, on Wednesday, April 24, 2024, following the close of trading on the

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that its industry-leading team of oncology experts will attend the American Association for Cancer Research (AACR) Annual

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Novocure management will

Novocure (NASDAQ: NVCR) gab heute bekannt, dass die klinische Phase-3-Studie METIS ihren primären Endpunkt erreicht hat und eine statistisch signifikante Verbesserung der Zeit bis zur

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has recently completed the acquisitions of three comprehensive treatment centers (“CTC”) in North Carolina.

Two of the

Charles River Laboratories International, Inc. (NYSE: CRL) today announced the publication of its 2023 Corporate Citizenship Report, which includes progress and results from 2022 and 2023. The 2023

Novocure (NASDAQ: NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for

Charles River Laboratories International, Inc. (NYSE: CRL) and National University of Singapore’s (NUS) Yong Loo Lin School of Medicine (NUS Medicine), a leading medical education institution with

Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics, Inc., a biotechnology company developing epigenetic gene therapies, today announced an AAV9 production program

VITAS Healthcare Corporation, a wholly-owned subsidiary of Chemed Corporation (“Chemed”) (NYSE: CHE), announced it entered into an agreement on March 12, 2024 to acquire all hospice operations and

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Barclays 26^th Annual Global Healthcare Conference on Wednesday, March 13^th, at 10:15 a.m. ET

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present at the Barclays 26th Annual Global Healthcare Conference, which is being held March 12 - 14, 2024, in

Novocure (NASDAQ: NVCR) today announced a late breaking abstract which reviews the results of an exploratory subgroup analysis of the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 (INNOVATE-3)

Chemed Corporation (NYSE:CHE) today announced that it will deliver a virtual presentation at the Oppenheimer 34th Annual Healthcare Conference on Tuesday, March 12, 2024, at approximately 12:00

Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that members of its management team will participate in a fireside chat at the Barclays

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present at the Raymond James 45^th Annual Institutional Investors Conference, which is being held March 3 - 6

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company